Anti-inflammatory signaling of a key protein in heart attack recovery
Official title: Anti-inflammatory Signaling of RNA-binding Protein, Tristetraprolin, During Myocardial Infarction
Funded at University of Hawaii at Manoa · NIH-11539056 · Data updated 2026-11-12
A study in people who have had a heart attack is exploring how a macrophage protein called Tristetraprolin may reduce inflammation and help protect heart tissue.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project start | July 20, 2026 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $248,999 |
| NIH project number | 4R00HL168433-03 |
| Project ID | NIH-11539056 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have had an acute myocardial infarction and are potential candidates for therapies targeting inflammatory pathways.
✕Less likely to help
Patients without significant inflammatory responses or those not undergoing related interventions may see little direct benefit.
What this research studies
This project looks at how Tristetraprolin in immune cells influences inflammation after a heart attack. It builds on prior work showing TTP may boost antioxidant activity and limit damaging ferroptosis in heart tissue. The research combines basic biology with approaches that could point toward new therapies to reduce heart damage and improve recovery.
Why it matters
Potential benefit: If successful, the work could lead to therapies that lessen heart damage after a heart attack and support better healing.
How similar studies have gone: Previous studies suggest targeting inflammatory pathways after heart attack can influence outcomes, but direct clinical translation remains exploratory.
Where this research is happening
-
University of Hawaii at Manoa
Honolulu, United States Active
Researchers
- Principal investigator: Yap, Jonathan — University of Hawaii at Manoa
- Study coordinator: Yap, Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Targeting RIPK3 to reduce heart damage after a heart attack
This grant studies a specific cell-death pathway (RIPK3) to protect the heart after a heart attack, with the goal of reducing damage and improving recovery.
-
mRNA lipid nanoparticles to help heart attack patients grow healthier blood vessels
A heart-attack study tests a new treatment that uses messenger RNA delivery with tiny fat bubbles to promote normal blood vessel growth in damaged heart tissue.
-
Targeted nanotherapy to calm inflammation, grow new blood vessels, and prevent scarring after a heart attack
A new treatment approach uses engineered secretions from immune cells delivered early after a heart attack to reduce inflammation, promote blood vessel growth, and limit scarring to protect heart function.
-
Why heart attacks and strokes affect people differently across places and races
This project follows adults across the U.S. to see how lifelong social and neighborhood factors shape heart attacks, heart failure, and recovery, with attention to Black adults and regions with high disease rates.
-
Real-time multi-lead ECG from wearables to help detect heart attacks early
A new AI-based approach uses everyday wearable sensors to turn simple PPG signals into multi-lead ECG data to monitor for heart attacks in real time, even outside the clinic.
-
Extreme heat and heart attack risk: who is most at risk and why
High heat and air pollution may raise the risk of heart attacks, and this project looks at who is most affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.